Reviewer's report

Title: Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in androgen-dependent prostate cancer

Version: 1 Date: 13 October 2010

Reviewer: srikala sridhar

Reviewer's report:

Overall a well written paper that aims to better understand EGFR as a target in prostate cancer.

Major Revisions.

1. The paper should include references to the trials that have been done exploring EGFR inhibitor in prostate cancer. (Gefitinib, Omnitarg, Lapatinib), as this highlights the disconnect between preclinical and clinical role of EGFR inhibitors, and the need to determine if a subset of pts are more likely to respond.

- Minor Essential Revisions

Introduction:
Second paragraph, Line 1 should be changed to ...molecular mechanisms responsible for PC
Line 2, Line 14: "Several evidences" and "clinical evidences" should be changed
Line 9: tshould be changed to ....types and to its role "as a" drug target

Materials and Methods
Line 4: forzen should be changed to frozen

Results;
Second paragraph: Line 2...should be changed from cytoplasmatic to cytoplasmic

Gene Profiling
Paragraph 1: should be changed to: "analysis on frozen tissue was performed."

Discussion
paragreaph 1: line 3: should be changed to: leading to the search for...
Line 3/4: suggest reword: The role of EGFR in PC progression......progression of PC
Line 5: arising shoudl be rising
Paragraph 4: substains should be changed to sustains

- Discretionary Revisions

These are recommendations for improvement which the author can choose to ignore. For example clarifications, data that would be useful but not essential.

A table showing the commonly recognized EGFR mutations may help for clarify.

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

NONE.